CAR-T cell therapy for relapsed B-cell cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial uses a patient's own T cells, modified to target a protein called CD19 on cancer cells, to treat B-cell cancers that have come back or not responded to standard treatments. It is for people aged 14 to 70 with certain types of leukemia or lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 70 years old.
- You have a B-cell cancer (like ALL or NHL) that has returned or not responded to standard treatment.
- Your cancer cells have at least 5% blasts (immature cells) in the bone marrow.
- You are able to have cells collected from your blood (apheresis).
- You have adequate organ function (heart, lungs, liver, kidneys) and blood counts.
- You have not had prior treatment with any CAR-T cell therapy or a CD19-targeted therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells, called CAR-T cells, that are made from a donor to attack cancer cells in people with B-cell blood cancers that have come back or not responded to standard treatments. The goal is to see if these cells can help people who haven't had success with other therapies.
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
This trial tests a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia (ALL) that has come back after treatment or is hard to treat. The therapy uses your own immune cells, modified to find and kill leukemia cells.
This trial tests a new CAR-T cell therapy (FIT-CD19-CAR-T) for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. The goal is to see if this treatment is safe and can help control the leukemia.
This trial tests a CAR-T cell therapy for people with certain types of blood cancer that have come back or not responded to standard treatment. The therapy targets specific markers on cancer cells to help your immune system fight the disease.
Hear when a new B-Cell Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.